NASDAQ
Kailera Therapeutics, Inc. (KLRA)
♥ 600 Thanks from members
Kailera Therapeutics, Inc. (KLRA) exhibits mixed market sentiment following its record-breaking obesity IPO. While its $1.17B cash runway and licensed Hengrui pipeline (including ribupatide) spark bullish interest, widening Q2 losses, a new 52-week low, and up to $5.7B in looming commercial milestones present steep downside risks.